| Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies RS Bhatta, H Chandasana, YS Chhonker, C Rathi, D Kumar, K Mitra, ... International journal of pharmaceutics 432 (1-2), 105-112, 2012 | 233 | 2012 |
| Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux RE Lee, JG Hurdle, J Liu, DF Bruhn, T Matt, MS Scherman, PK Vaddady, ... Nature medicine 20 (2), 152-158, 2014 | 189 | 2014 |
| Clinical pharmacology of bispecific antibody constructs C Rathi, B Meibohm The Journal of Clinical Pharmacology 55 (S3), S21-S28, 2015 | 45 | 2015 |
| Translational PK/PD of anti-infective therapeutics C Rathi, RE Lee, B Meibohm Drug Discovery Today: Technologies 21, 41-49, 2016 | 34 | 2016 |
| Bioanalytical method development and validation of natamycin in rabbit tears and its application to ocular pharmacokinetic studies RS Bhatta, H Chandasana, C Rathi, D Kumar, YS Chhonker, GK Jain Journal of pharmaceutical and biomedical analysis 54 (5), 1096-1100, 2011 | 32 | 2011 |
| Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS … NM Midde, MA Rahman, C Rathi, J Li, B Meibohm, W Li, S Kumar PloS one 11 (2), e0149225, 2016 | 27 | 2016 |
| Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections DF Bruhn, SL Waidyarachchi, DB Madhura, D Shcherbakov, Z Zheng, ... Science translational medicine 7 (288), 288ra75-288ra75, 2015 | 23 | 2015 |
| Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors AB El-Khoueiry, J Clarke, T Neff, T Crossman, N Ratia, C Rathi, P Noto, ... British journal of cancer 129 (2), 309-317, 2023 | 18 | 2023 |
| LC–MS method for determination of amphotericin B in rabbit tears and its application to ocular pharmacokinetic study RS Bhatta, C Rathi, H Chandasana, D Kumar, YS Chhonker, GK Jain Chromatographia 73 (5), 487-493, 2011 | 14 | 2011 |
| Population Pharmacokinetics of Belantamab Mafodotin, a BCMA‐targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma C Rathi, J Collins, H Struemper, J Opalinska, RC Jewell, G Ferron‐Brady CPT: Pharmacometrics & Systems Pharmacology, 2021 | 13 | 2021 |
| Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis PK Vaddady, A Trivedi, C Rathi, DB Madhura, J Liu, RE Lee, B Meibohm European Journal of Pharmaceutical Sciences 127, 233-239, 2019 | 12 | 2019 |
| Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma G Ferron‐Brady, C Rathi, J Collins, H Struemper, J Opalinska, S Visser, ... Clinical Pharmacology & Therapeutics, 2021 | 11 | 2021 |
| Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis S Wagh, C Rathi, PB Lukka, K Parmar, Z Temrikar, J Liu, MS Scherman, ... Antimicrobial Agents and Chemotherapy, AAC. 01744-20, 2021 | 11 | 2021 |
| Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice C Rathi, PB Lukka, S Wagh, RE Lee, AJ Lenaerts, M Braunstein, A Hickey, ... Tuberculosis 114, 119-122, 2019 | 10 | 2019 |
| Exposure-response (ER) for ocular safety endpoints for belantamab mafodotin (belamaf), a B-Cell Maturation Antigen (BCMA)-targeting agent, in patients with relapsed/refractory … G Ferron-Brady, C Rathi, J Collins, H Struemper, J Opalinska, RC Jewell Blood 136, 20-21, 2020 | 4 | 2020 |
| A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. DJ Cohen, S Pant, B O'Neil, J Marinis, J Winnberg, CM Ahlers, J Callaway, ... Journal of Clinical Oncology 37 (15_suppl), TPS4165-TPS4165, 2019 | 4 | 2019 |
| Pharmacokinetics of Peptides and Proteins C Rathi, B Meibohm Reviews in Cell Biology and Molecular Medicine 1 (2), 300-326, 2006 | 4 | 2006 |
| Abstract CT196: Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM): Application of … G Ferron-Brady, C Rathi, J Collins, H Struemper, J Opalinska, RC Jewell Cancer Research 80 (16 Supplement), CT196-CT196, 2020 | 3 | 2020 |
| Should Race‐Genotype Interactions Be Considered in the Global Development of CYP2C19 Substrates? A Proposed Framework Using Physiologically Based Pharmacokinetic Modeling C Patel, C Rathi, K Venkatakrishnan The Journal of Clinical Pharmacology 57 (4), 417-421, 2017 | 3 | 2017 |
| Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation in the Development of Spectinamides, a Novel Class of Anti-Tuberculosis Agents C Rathi The University of Tennessee Health Science Center, 2017 | 2 | 2017 |
